Thomas Tedder

Last updated

Thomas Fletcher Tedder, Ph.D., (born May 14, 1956) is an American immunologist. He is best known for his work in the fields of B lymphocyte biology and regulation. He is currently the Alter E. Geller Professor for Research in Immunology at Duke University. [1]

Duke University Private university in Durham, North Carolina, United States

Duke University is a private research university in Durham, North Carolina. Founded by Methodists and Quakers in the present-day town of Trinity in 1838, the school moved to Durham in 1892. In 1924, tobacco and electric power industrialist James Buchanan Duke established The Duke Endowment and the institution changed its name to honor his deceased father, Washington Duke.

Career

Tedder received his Ph.D. in molecular cell biology from the University of Alabama in 1984 and completed his postdoctoral training as a Research Fellow in Pathology at Harvard Medical School. He was a faculty member at Dana-Farber Cancer Institute and Harvard Medical School from 1985 to 1998 before joining Duke University in 1993 as its founding Chairman of Immunology. [2] Tedder studies the structure and function of B lymphocyte cell surface molecules that regulate B cell function, activation, and signal transduction. He currently has 401 total publications and 25 issued patents relating to B cells and their products, including CD19, CD20, CD22, CD83, and L-selectin. [3] He has founded four biotherapeutic companies, including Angelica Therapeutics, Cellective Therapeutics, Cellective BioTherapy [4] and most recently, Antigenomycs, Inc.

University of Alabama public university located in Tuscaloosa, Alabama, United States

The University of Alabama is a public research university in Tuscaloosa, Alabama. Established in 1820, the University of Alabama (UA) is the oldest and largest of the public universities in Alabama as well as the flagship of the University of Alabama System. The university offers programs of study in 13 academic divisions leading to bachelor's, master's, Education Specialist, and doctoral degrees. The only publicly supported law school in the state is at UA. Other academic programs unavailable elsewhere in Alabama include doctoral programs in anthropology, communication and information sciences, metallurgical engineering, music, Romance languages, and social work.

Harvard Medical School Medical school in Boston, MA

Harvard Medical School (HMS) is the graduate medical school of Harvard University. It is located in the Longwood Medical Area of the Mission Hill neighborhood in Boston, Massachusetts. Founded in 1782, HMS is one of the oldest medical schools in the United States and is consistently ranked 1st among research-oriented medical schools by U.S. News and World Report. Unlike most other leading medical schools, HMS does not operate in conjunction with a single hospital but is directly affiliated with several teaching hospitals in the Boston area. The HMS faculty has approximately 2,900 full- and part-time voting faculty members consisting of assistant, associate, and full professors, and over 5,000 full- and part-time, non-voting instructors. The majority of the faculty receive their appointments through an affiliated teaching hospital.

Related Research Articles

CD20 protein-coding gene in the species Homo sapiens

B-lymphocyte antigen CD20 or CD20 is expressed on the surface of all B-cells beginning at the pro-B phase and progressively increasing in concentration until maturity.

Emil Raphael Unanue (born September 13, 1934) is an immunologist and the current Paul & Ellen Lacy Professor at Washington University School of Medicine. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences and the Institute of Medicine. He previously served as chair of the National Academy of Sciences Section of Microbiology and Immunology.

CD19 protein-coding gene in the species Homo sapiens

B-lymphocyte antigen CD19, also known as CD19 molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12 and CVID3 is a transmembrane protein that in humans is encoded by the gene CD19. In humans, CD19 is expressed in all B lineage cells, except for plasma cells, and in follicular dendritic cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies.

Ralph M. Steinman Canadian immunologist and cell biologist

Ralph Marvin Steinman was a Canadian physician and medical researcher at Rockefeller University, who in 1973 discovered and named dendritic cells while working as a postdoctoral fellow in the laboratory of Zanvil A. Cohn, also at Rockefeller University. Steinman was one of the recipients of the 2011 Nobel Prize in Physiology or Medicine.

LAG3 protein-coding gene in the species Homo sapiens

Lymphocyte-activation gene 3, also known as LAG-3, is a protein which in humans is encoded by the LAG3 gene. LAG3, which was discovered in 1990 and was designated CD223 after the Seventh Human Leucocyte Differentiation Antigen Workshop in 2000, is a cell surface molecule with diverse biologic effects on T cell function. It is an immune checkpoint receptor and as such is the target of various drug development programs by pharmaceutical companies seeking to develop new treatments for cancer and autoimmune disorders. In soluble form it is also being developed as a cancer drug in its own right.

Harald von Boehmer German-Swiss immunologist

Harald von Boehmer was a German/Swiss immunologist best known for his work on T lymphocytes.

Sir William Dunn School of Pathology

The Sir William Dunn School of Pathology is a Department within the University of Oxford. Its research programme includes the cellular and molecular biology of pathogens, the immune response, cancer and cardiovascular disease. It teaches undergraduate and graduate courses in the medical sciences.

Steven J. Burakoff is a cancer specialist and the author of both Therapeutic Immunology (2001) and Graft-Vs.-Host Disease: Immunology, Pathophysiology, and Treatment (1990).

Timothy "Tim" A. Springer, Ph.D. is an immunologist and Latham Family Professor at Harvard Medical School. Springer is best known for his pioneering work in discovering the first integrins and intercellular adhesion molecules (ICAMs) and elucidating how these cell adhesion molecules function in the immune system. His innovative use of monoclonal antibodies in his research paved the way for the development of therapeutic antibodies, known as selective adhesion molecule inhibitors, to treat autoimmune diseases. In recent years, Springer's research interest has expanded to include malaria, transforming growth factor beta (TGF-β) signaling molecules, and von Willebrand factor.

Professor Chris Goodnow BVSc, PhD, FAA FRS MNAS is an immunology researcher and the current Executive Director of the Garvan Institute of Medical Research. He holds the Bill and Patricia Ritchie Foundation Chair and is a Conjoint Professor in the Faculty of Medicine at UNSW Sydney. He holds dual Australian and US citizenship.

Robert F. Siliciano is a professor of medicine at the Johns Hopkins University School of Medicine and an investigator with the Howard Hughes Medical Institute. Siliciano (sill-ih-CAH-noh) has a joint appointment in the Department of Molecular Biology and Genetics at Johns Hopkins. Siliciano researches the mechanisms by which the human immunodeficiency virus (HIV) remains latent in the human body.

Frederick W. Alt is an American geneticist. He is a member of the Immunology section of the National Academy of Sciences and a Charles A. Janeway Professor of Pediatrics, and Professor of Genetics at Harvard Medical School. He is the Director of the Program in Cellular and Molecular Medicine at the Boston Children's Hospital. He is a Howard Hughes Medical Institute investigator since 1987.

Andrew D. Luster is the Persis, Cyrus and Marlow B. Harrison Professor of Medicine at Harvard Medical School, and the Chief of the Division of Rheumatology, Allergy and Immunology at Massachusetts General Hospital. He is Director of its Research Center for Immunology and Inflammatory Diseases, and a member of the Dana-Farber/Harvard Cancer Center's Cancer Immunology program.

Harvey Cantor

Harvey Cantor is an American immunologist known for his studies of the development and immunological function of T lymphocytes. Cantor is currently the Baruj Benacerraf Professor of Microbiology & Immunobiology at the Harvard Medical School.

Doreen CantrellCBE, FRS, FRSE, FMedSci, is a scientist and Professor of Cellular Immunology at the School of Life Sciences, University of Dundee. She researches the development and activation T lymphocytes, which are key to the understanding the immune response.

Max Dale Cooper American immunologist and Professor of Pathology & Laboratory Medicine at Emory University

Max Dale Cooper, ForMemRS, is an American immunologist and Professor of Pathology at Emory University known for identifying T cells and B cells.

Gordon M. Keller is a Canadian scientist recognized for his research on applying developmental biology findings to in vitro pluripotent stem cell differentiation. He is currently a Senior Scientist at the Ontario Cancer Institute, a Professor at the University of Toronto and the director of the McEwen Centre for Regenerative Medicine.

Andrew McMichael Professor of Molecular Medicine, Immunologist

Sir Andrew James McMichael, is an immunologist, Professor of Molecular Medicine, and previously Director of the Weatherall Institute of Molecular Medicine at the University of Oxford. He is particularly known for his work on T cell responses to viral infections such as influenza and HIV.

Bruce Alan Sullenger is the Joseph W. and Dorothy W. Beard Professor of Experimental Surgery at the Duke University School of Medicine, the Founding Director of the Duke Translational Research Institute (DTRI) which he led from 2006-2016, and the Associate Director for Translation in the Duke Cancer Institute (DCI).

Garnett Herrel Kelsoe is an American immunologist and the James B. Duke Professor of Immunology at Duke University School of Medicine.

References

  1. "Duke Immunology". immunology.duke.edu. Archived from the original on 2016-08-03. Retrieved 11 August 2018.
  2. "Archived copy". Archived from the original on 2015-09-12. Retrieved 2015-10-19.CS1 maint: Archived copy as title (link)
  3. "Angelica Therapeutics: Best in Class Fusion Toxins". angelicatherapeutics.com. Retrieved 11 August 2018.
  4. "Article". www.bizjournals.com. 2015.